RxDoctor Payments Data

Kartik Sivaraaman, MD

Neurology · Richmond, VANPI 1962651026

Payments from drug & device makers

$11,500in general payments, 2019–2025

Across 276 payments — averaging $41.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$3K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Bristol Myers Squibb$2K
  • AbbVie$886
  • Argenx US, Inc.$515
  • Supernus Pharmaceuticals, Inc.$352
  • plus $3K from 52 others

What the payments were for

  • Consulting fees$4,40038%
  • Speaking & faculty fees$390%
  • Travel & lodging$1,11510%
  • Food & beverage$5,94552%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
SK Life Science, Inc.8$2,661
E.r. Squibb & Sons, L.L.C.4$2,198
Bristol Myers Squibb14$1,628
AbbVie45$886
Argenx US, Inc.18$515
Supernus Pharmaceuticals, Inc.29$352
AstraZeneca(2 entities)14$304
CSL Behring9$217
Jazz Pharmaceuticals Inc.9$206
UCB, Inc.8$155
Sunovion Pharmaceuticals Inc.8$131
Lundbeck LLC7$127
Eisai Inc.6$117
Sumitomo Pharma America, Inc.5$101
DIXI Medical USA Corp1$97
Novartis5$94
Akcea Therapeutics, Inc.1$91
EMD Serono, Inc.5$88
Avion Pharmaceuticals5$83
Merz Pharmaceuticals, LLC4$80
Otsuka America Pharmaceutical, Inc.4$80
Livanova USA, Inc.1$77
Grifols USA, LLC4$76
Biohaven Pharmaceuticals, Inc.6$76
Biogen2$68
Neurelis, Inc.4$67
Impel Pharmaceuticals LLC3$61
Pfizer3$53
Aucta Pharmaceuticals, Inc.2$50
Amneal Pharmaceuticals LLC3$49
Teva Pharmaceuticals USA, Inc.3$47
Johnson & Johnson(2 entities)2$44
Biohaven Pharmaceutical Holding Company Ltd.3$42
Merck3$40
Acorda Therapeutics, Inc2$39
Takeda Pharmaceuticals U.S.A., Inc.1$35
Genentech USA, Inc.1$35
Mallinckrodt Hospital Products Inc.1$32
Currax Pharmaceuticals LLC2$30
Scilex Pharmaceuticals Inc.2$30
Lilly USA, LLC2$27
Hoffmann-la Roche Limited1$25
Alnylam Pharmaceuticals Inc.1$25
TG Therapeutics, Inc.1$25
Abbott1$24
Ipsen Biopharmaceuticals, Inc1$21
Harmony Biosciences LLC1$19
Inspire Medical Systems, Inc.1$19
Axsome Therapeutics, Inc.1$17
Greenwich Biosciences, Inc.1$17
Catalyst Pharmaceuticals, Inc.1$17
Avanir Pharmaceuticals, Inc.1$17
Impel Pharmaceuticals Inc.1$16
GE HealthCare1$15
Boston Scientific1$15
Tanabe Pharma America, Inc.1$15
Neurocrine Biosciences, Inc.1$13
Amgen1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,500 in reported general payments places this provider in the 70th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$200,311
Medicare patients
431
Services billed
2,139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Levetiracetam77$2,624
Levetiracetam ErLevetiracetam22$947
Gabapentin53$622
Carbidopa-LevodopaCarbidopa/Levodopa15$156
Donepezil Hcl12$150

Paid to pharmacies, not to this prescriber.

Other neurology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →